A phase Ib/II study of ARQ 761 in patients selected for tumours with high levels of the biomarker NQ01
Phase of Trial: Phase I/II
Latest Information Update: 04 May 2016
At a glance
- Drugs ARQ 761 (Primary) ; Gemcitabine; Paclitaxel
- Indications Pancreatic cancer
- Focus Adverse reactions; Therapeutic Use
- 04 May 2016 According to an ArQule media release, the first cohort of patients has been enrolled in this trial.
- 04 May 2016 According to an ArQule media release, status changed from planning to recruiting.
- 10 Apr 2015 New trial record